LivaNova (NSDQ:LIVN) said today that its Perceval sutureless implant is safe and effective compared to standard aortic valve replacement, according to a clinical study. The study, presented at the 100th annual meeting of the American Association of Thoracic Surgery (AATS), revealed that the Perceval sutureless surgical aortic valve demonstrated freedom from major adverse cerebral and cardiovascular […]
LivaNova touts results of VNS treatment for bipolar depression
LivaNova (NSDQ:LIVN) today announced the publication of a new study that showed adding vagus nerve stimulation (VNS) therapy to treatment-as-usual significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD). Published in the International Journal of Bipolar Disorders, the study examined patients from a 5-year prospective registry and found 63% of 97 patients treated with VNS plus […]
LivaNova cardiopulmonary devices can be used longer under FDA coronavirus guidance
LivaNova (NSDQ:LIVN) announced that some of its cardiopulmonary products are now permitted for extended use in specific therapies after the FDA expanded device availability amid the COVID-19 pandemic. On April 6, the FDA issued guidance to temporarily expand the availability of certain devices in an effort to address the coronavirus crisis. Along the guidelines given by […]
LivaNova lands CE Mark for depression neurostimulation treatment
LivaNova (NSDQ:LIVN) said today that its vagus nerve stimulation therapy for treatment-resistant depression has won the CE Mark in Europe. Two patients in the United Kingdom were implanted with the company’s Symmetry system at the Musgrove Park Hospital in Taunton, England, making them the first patients to receive Symmetry devices outside the United States. The ability […]
Is Medtronic eyeing LivaNova for a takeover?
Some industry analysts are speculating that Medtronic (NYSE:MDT) might want to acquire LivaNova (NSDQ:LIVN) for its neuromodulation business. A source told financial intelligence company Reorg last week that someone pitched the idea to Medtronic, which would divest LivaNova’s cardiovascular business and “certain MDT cardiac surgery products.” “Five sector advisors said such a deal would make sense as […]
LivaNova adds Verily to depression study
LivaNova (NSDQ:LIVN) announced that it has added Google’s (NSDQ:GOOGL) Verily to its study of vagus nerve stimulation (VNS) therapy for difficult-to-treat depression (DTD). The Recover clinical will gather quantitative data on patient behavior using Verily’s technology and analytics. The data could help the researchers understand depressive episodes and the patient’s response to treatment. Study participants will […]
LivaNova pulls the plug on transcatheter mitral valve repair device
LivaNova (NSDQ:LIVN) said today that it is ending its Caisson Interventional transcatheter mitral valve replacement (TMVR) program and plans to restructure its heart valve business to improve profitability. The company’s heart valve business represented nearly $130 million in revenue during fiscal 2018 and saw its revenue numbers decline over the last five years, both with biological […]
LivaNova slumps on Q3 revenues miss
LivaNova (NSDQ:LIVN) shares slumped in early trading today after the medical device company reported lower-than-expected third-quarter revenues, despite a swing to black ink and a health beat on earnings. London-based LivaNova posted profits of $32.1 million, or 66¢ per share, on sales of $268.6 million for the three months ended Sept. 30. That compares with losses […]
LivaNova recalls VNS generators
LivaNova (NSDQ:LIVN) is recalling some of its Model 1000 SenTiva vagus nerve stimulation therapy (VNS) generators, which may reset themselves during therapy. A component supplied by an outside company produces an error that causes the generator to reset and fail to deliver the intended VNS therapy, according to London-based LivaNova. Resets may occur during routine […]
LivaNova launches vagus nerve stim depression study
LivaNova (NSDQ:LIVN) said last week that it enrolled its first patient in a study of vagus nerve stimulation therapy for treatment-resistant depression. The Recover study is designed to determine whether active VNS therapy is a superior option compared to a no-stimulation control in producing a reduction in baseline symptom severity of depression. LivaNova plans to enroll […]
LivaNova wins Medicare nod for nerve stimulation trial
Medicare has approved a LivaNova (NSDQ:LIVN) study of vagus nerve stimulation (VNS) to treat depression, the company said today. The Centers for Medicare and Medicaid Services accepted the London-based company’s protocol for a clinical trial to study the safety and effectiveness of adding VNS to traditional depression treatment in patients with treatment-resistant depression. Approval of […]
- 1
- 2
- 3
- …
- 9
- Next Page »
